Form 10-Q · Quarterly report
Viatris 10-Q, filed Aug 6, 2026
- Filed
- CIK
- 0001792044
- Accession no.
- 0001792044-26-000041
Summary
Viatris filed its quarterly report on Form 10-Q for the period ended June 30, 2026, whose management discussion and analysis restates the company's business overview and the risk factors that could cause actual results to differ from its forward-looking statements. The filing notes interim results are not necessarily indicative of full-year performance and describes the company's four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Key points
- Viatris reports operations in more than 165 countries and territories with approximately 30,000 employees, 27 manufacturing, packaging and distribution sites, and roughly 1,300 approved molecules.
- Viatris says it supplies medicines to approximately 1 billion patients worldwide each year.
- Viatris' four reportable segments are Developed Markets, Greater China, JANZ, and Emerging Markets, the last of which includes its ARV franchise and presence in more than 125 countries.
- Viatris states that interim results for the three and six months ended June 30, 2026 are not necessarily indicative of full fiscal year results.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis addresses material changes in the financial condition and results of operations of Viatris Inc. and subsidiaries for the periods presented. Unless context requires otherwise, the “Company,” “Viatris,” “our” or “we” refer to Viatris Inc. and its subsidiaries. This discussion and analysis should be read in conjunction with the Consolidated Financial Statements, the related Notes to Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Viatris’ 2025 Form 10-K, the unaudited interim…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.